Cancer overdiagnosis and overtreatment

Current Opinion in Urology

Volumn 22, Issue 3, 2012, Pages 203-209

  Klotz, Laurence ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

cancer overdiagnosis; cancer overtreatment; early detection; screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

AUTOPSY; BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER OVERDIAGNOSIS; CANCER SCREENING; CANCER SURVIVAL; CANCER THERAPY; COMPUTER ASSISTED TOMOGRAPHY; EARLY DIAGNOSIS; HUMAN; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; THYROID CANCER; ULTRASOUND;

DISEASE PROGRESSION; EARLY DETECTION OF CANCER; EVIDENCE-BASED MEDICINE; HUMANS; MALE; MASS SCREENING; POPULATION SURVEILLANCE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; UNNECESSARY PROCEDURES; WATCHFUL WAITING;

EID: 84859630717     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32835259aa     Document Type: Review

References (35)

1. Dorland WAN. Dorland's illustrated medical dictionary. 28th ed. Philadelphia, PA: W.B. Saunders Company; 1994.
2. Feinstein AR. Symptoms as an index of biological behaviour and prognosis in human cancer. Nature 1966; 209:241-245.
3. Mooi WJ, Peeper DS. Oncogene-induced cell senescence - halting on the road to cancer. N Engl J Med 2006; 355:1037-1046. (Pubitemid 44343547)
4. Folkman J, Kalluri R. Cancer without disease. Nature 2004; 427:787. (Pubitemid 38297724)
5. Serrano M. Cancer regression by senescence. N Engl J Med 2007; 356:1996-1997.
6. Sakr WA, Grignon DJ, Haas GP, et al. Age and racial distribution of prostatic intraepithelial neoplasia. Eur Urol 1996; 30:138-144. (Pubitemid 26285528)
7. Stamatiou K, Alevizos A, Agapitos E, Sofras F. Incidence of impalpable carcinoma of the prostate and of nonmalignant and precarcinomatous lesions in Greek male population: an autopsy study. Prostate 2006; 66:1319-1328. (Pubitemid 44389158)
8. Damiano R, Lorenzo GD, Cantiello F, et al. Clinicopathologic features of prostate adenocarcinoma incidentally discovered at the time of radical cystectomy: an evidence-based analysis. Eur Urol 2007; 52:648-657. (Pubitemid 47126188)
9. Harach HR, Franssila KO, Wasenius V. Occult papillary carcinoma of the thyroid: a 'normal' finding in Finland. A systematic autopsy study. Cancer 1985; 56:531-538. (Pubitemid 15035581)
10. Welch HG, Black WC. Using autopsy series to estimate the disease 'reservoir'for ductal carcinoma in situ of the breast: how much more breast cancer can we find? Ann Intern Med 1997; 127:1023-1028. (Pubitemid 27516615)
11. Welch G, Black WC. Overdiagnosis in cancer. J Natl Cancer Inst 2010; 102:605-613. This is an excellent summary of the issues discussed in this chapter from an epidemiological perspective. For those wishing further information, see also the book 'Overdiagnosis' by G. Welch.
12. Ries LAG, Melbert D, Krapcho M, et al. SEER cancer statistics review, 1975-2005. Bethesda, MD: National Cancer Institute; 2008. Based on November 2007 SEER data submission, posted to the SEER Web site. http://seer.cancer.gov/csr/ 1975-2005/. [Accessed 18 August 2009]
13. Merrill RM, Feuer EJ, Warren JL, et al. Role of transurethral resection of the prostate in population-based prostate cancer incidence rates. Am J Epidemiol 1999; 150:848-860. (Pubitemid 29482838)
14. Zackrisson S, Andersson I, Janzon L, et al. Rate of overdiagnosis of breast cancer 15 years after end of Malmömammographic screening trial: follow-up study. BMJ 2006; 332:689-692.
15. Welch HG, Schwartz LM, Woloshin S. Ramifications of screening for breast cancer 1 in 4 cancers detected by mammography are pseudocancers. BMJ 2006; 332:727. (Pubitemid 44365697)
16. Jemal A. Cancer statistics 2012. CA Cancer J Clin 2010; 62:10-29.
17. Andriole GL, Grubb RL, Buys SS, et al., PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360:1310-1319. These two critically important articles, published in the same issue of the New England Journal of Medicine, illustrate the difficulties of proving thebenefits of screening. Both studies were large, and as carefully implemented as possible. The Andriole study, based in the USA, found no benefit; the Schroder study, based in Europe, reported a 20-31% mortality reduction. The Andriole study had a high rate of contamination, fewer numbers, and shorter follow-up, which may explain the negative result.
18. Schroder FH, Hugosson J, Roobol MJ, et al., ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320-1328. These two critically important articles, published in the same issue of the New England Journal of Medicine, illustrate the difficulties of proving thebenefits of screening. Both studies were large, and as carefully implemented as possible. The Andriole study, based in the USA, found no benefit; the Schroder study, based in Europe, reported a 20-31% mortality reduction. The Andriole study had a high rate of contamination, fewer numbers, and shorter follow-up, which may explain the negative result.
19. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95:868-878. (Pubitemid 36833878)
20. Bessho F. Where should neuroblastoma mass screening go? Lancet 1996; 348:1672. (Pubitemid 27007523)
21. Pohl H, Welch HG. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97:142-146. (Pubitemid 40277094)
22. Davies L, Welch HG. The increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006; 295:2164-2167.
23. Dennis LK. Analysis of the melanoma epidemic, both apparent and real: data from the 1973 through 1994 surveillance, epidemiology, and end results program registry. Arch Dermatol 1999; 135:275-280. (Pubitemid 29159209)
24. Crispen PL, Viterbo R, Boorjian SA, et al. Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer 2009; 115:2844-2852.
25. Volpe A, Jewett MA. The natural history of small renal masses. Nat Clin Pract Urol 2005; 2:384-390. (Pubitemid 43114969)
26. Zhang J, Kang SK, Wang L, et al. Distribution of renal tumor growth rates determined by using serial volumetric CT measurements. Radiology 2009; 250:137-144.
27. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11:725-732. This screening study, which had the longest follow up of any randomized prostate cancer screening study (14 years), was strongly positive. It represents the strongest evidence for a mortality reduction with screening for prostate cancer.
28. Raffle AE, Muir Gray JA. Screening: evidence and practice. New York, NY: Oxford University Press; 2007. p. 68.
29. Nadler RB, Loeb S, Roehl KA, et al. Use of 2.6ng/ml prostate specific antigen prompt for biopsy in men older than 60 years. J Urol 2005; 174:2154-2157. (Pubitemid 41611762)
30. MacMahon H, Austin JH, Gamsu G, et al. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. Radiology 2005; 237:395-400. (Pubitemid 41507873)
31. Song JH, Chaudhry FS, Mayo-Smith WW. The incidental adrenal mass on CT: prevalence of adrenal disease in 1049 consecutive adrenal masses in patients with no known malignancy. Am J Roentgenol 2008; 190:1163-1168. (Pubitemid 351684914)
32. International Early Lung Cancer Early Action Program Investigators. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006; 355:1763-1771.
33. Campbell PA, Conrad RJ, Campbell CM, et al. Papillary urothelial neoplasm of low malignant potential: reliability of diagnosis and outcome. BJU Int 2004; 93:1228-1231. (Pubitemid 38823942)
34. Jones TD, Cheng L. Papillary urothelial neoplasm of low malignant potential: evolving terminology and concepts. J Urol 2006; 175:1995-2003. (Pubitemid 43668551)
35. Esserman L, Shieh Y, Thompson I. Rethinking screening for breast cancer and prostate cancer. JAMA 2009; 302:1685-1692.